An expert consensus for the adjustment of treatment strategies in patients with chronic hepatitis B treated with non-first-line nucleos(t)ide analogues.
10.3760/cma.j.issn.1007-3418.2019.05.004
- VernacularTitle:非一线核苷(酸)类似物经治慢性乙型肝炎患者治疗策略调整专家共识
- Collective Name:Hepatitis Group, Chinese Society of Hepatology;Chinese Medical Association; Chinese Journal of Hepatology
- Publication Type:Journal Article
- Keywords:
Consensus;
Hepatitis B, chronic;
Nucleos(t)ide analogues;
Treatment experienced;
Treatment strategy
- MeSH:
Antiviral Agents/therapeutic use*;
Consensus;
Guidelines as Topic/standards*;
Hepatitis B virus;
Hepatitis B, Chronic/drug therapy*;
Humans;
Nucleosides/therapeutic use*;
Outcome Assessment, Health Care/methods*;
Practice Guidelines as Topic;
Treatment Outcome
- From:
Chinese Journal of Hepatology
2019;27(5):343-346
- CountryChina
- Language:Chinese
-
Abstract:
Oral nucleos(t)ide analogues (NAs) is one of the main and efficient way for the treatment of chronic hepatitis B (CHB). Considering the antiviral potency and drug resistance of domestic and foreign guidelines, NAs are divided into first-line and non-first-line drugs. "An Expert Consensus for the Adjustment of Treatment Strategies in Patients with Chronic Hepatitis B Treated with Non-first-line Nucleos(t)ide Analogues," is mainly aimed at those patients who are currently using non-first-line NAs drugs. In addition, how to standardize the adjustment to first-line NAs drugs of choice, which can strengthen the effectiveness of initial antiviral treatment to obtain better antiviral efficacy, and improve patient compliance, coinciding with the avoidance of occurrence of serious drug adverse reactions in patients with CHB is presented.
